Alison Tree

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler et al. · The Lancet Oncology · 2019 · 519 citations · Full text

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis

Piet Ost, Barbara Alicja Jereczek‐Fossa, Nicholas van As et al. · European Urology · 2015 · 283 citations

Adaptive Radiotherapy, Urology, Surgical Oncology +6

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet et al. · The Lancet Oncology · 2022 · 280 citations · Full text

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy

Gerard G. Hanna, Louise Murray, R. Patel et al. · Clinical Oncology · 2017 · 267 citations · Full text

Adaptive Radiotherapy, Radiation Medicine, Medical Imaging +8

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Nicholas van As, Clare Griffin, Alison Tree et al. · New England Journal of Medicine · 2024 · 172 citations · Full text